The detection of balanced translocation carrying embryos has always been one of the difficulties for reproductive and genetic researchers at home and abroad. Due to the potential risk of balanced translocation carrier gametes, it is necessary to detect translocation embryos in order to achieve eugenics, but there are still some difficulties in detecting translocation embryos. Due to the lack of a very mature technology, there are no guidelines or expert consensus on the differentiation of translocation embryos at home and abroad, and finding the breakpoint of balanced translocation has been one of the hotspots of cytogenetics research. And because of the particularity of translocation embryo chromosome, it is impossible to distinguish normal embryo from translocation embryo by a single method.

With the continuous development of genetic diagnosis technology, the new diagnostics methods emerge in endlessly, in 2018, Basecare cooperate with a well-known reproductive medical institution in Shanghai to offer pre-implantation balanced translocation carriers detection. The hospital authorized Basecare as the sole provider of the industrialized service of the technology to assist the technology to achieve rapid clinical translation and application. Taking this medical institution as the lead unit, Basecare invites regional representative units across the country to establish the "China PGH Diagnostic Technology Research Alliance" to carry out multi-center large-sample clinical research on balanced translocation PGH diagnostic technology, accumulating a solid data foundation for PGH testing. It has confirmed the clinical reliability and accuracy of PGH technology. At present, PGH detection technology has been trusted by many reproductive centers. Basecare joint the medical institutions, with a number of units to cooperate, success for multiple balanced translocation family fertility healthy offspring with technical means, help thousands of balanced translocation family get over the pain of reproductive failure.